View clinical trials related to Hepatic Neoplasm Malignant.
Filter by:Primary Objective: - To evaluate the efficacy of SECOX regimen by adding oxaliplatin plus capecitabine to sorafenib versus sorafenib alone as palliative treatment for unresectable HCC patients to prolong overall survival (OS) for advanced HCC patients. Secondary Objective: - To compare the efficacy of SECOX regimen with Sorafenib alone for progression free survival (PFS) - To compare the efficacy of SECOX regimen with Sorafenib alone for response rate (RR) - To assess the overall safety profile of SECOX regimen in comparison of Sorafenib alone